Sagimet Biosciences is actively engaged in the research and development of Denifanstat, a selective FASN inhibitor, for the treatment of MASH. This segment focuses on addressing the underlying metabolic dysfunction that drives the progression of MASH, aiming to reduce liver inflammation, fibrosis, and steatosis. The company's clinical trials, including the recent positive Phase 3 results, demonstrate Denifanstat's potential to meet primary and secondary endpoints compared to placebo. By targeting FASN, a key enzyme in de novo lipogenesis, Denifanstat offers a novel approach to managing MASH and improving patient outcomes. Future opportunities include expanding clinical trials to diverse patient populations and exploring combination therapies to enhance efficacy.

Sagimet Biosciences is developing TVB-3567, a FASN inhibitor, for the treatment of acne. This segment aims to address the excessive sebum production and inflammation associated with acne vulgaris. By inhibiting FASN, TVB-3567 seeks to reduce lipid synthesis in sebaceous glands, thereby decreasing sebum production and alleviating acne symptoms. The company is conducting clinical trials to evaluate the safety and efficacy of TVB-3567 in acne patients. This therapeutic area represents a significant market opportunity, as acne affects a large population worldwide. Future development may include exploring topical formulations and combination therapies to optimize treatment outcomes and improve patient compliance.

Sagimet Biosciences is also pursuing oncology programs leveraging FASN inhibition to target cancer cells. This segment focuses on developing therapies that disrupt lipid metabolism in cancer cells, which rely on de novo lipogenesis for growth and survival. By inhibiting FASN, Sagimet aims to selectively target and kill cancer cells while sparing healthy cells. The company is conducting preclinical and clinical studies to evaluate the potential of FASN inhibitors in various cancer types. This therapeutic area represents a significant opportunity to develop novel cancer treatments with improved efficacy and reduced toxicity. Future research may include identifying specific biomarkers to predict patient response and developing personalized treatment strategies.